Dendreon Corporation (DNDN) - NASDAQ
DNDN is defunct.
  • Jun. 28, 2013, 10:10 AM

    Dendreon (DNDN +4.4%) jumps after the CHMP renders a positive opinion on Provenge for the "treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer." It will be interesting to watch how analysts react given the drug's Q1 numbers.

    | Jun. 28, 2013, 10:10 AM | 3 Comments
  • Jun. 28, 2013, 9:11 AM
    Premarket gainers: AMSC +13%. DNDN +11%. MCP +8%. ACI +6%. PTR +5%.
    Losers: CDTI -35%. BBRY -23%. AMED -23%. ACN -9%.
    | Jun. 28, 2013, 9:11 AM | 1 Comment
  • May 31, 2013, 8:28 AM

    For what it's worth — which, after Q1's sales figures (I, II, III) may not be much, at least in terms of analysts' opinions — Dendreon (DNDN) says six abstracts highlighting data from Phase 2 trials with Provenge will be presented at the the 49th Annual Meeting of the American Society of Clinical Oncology. The news seems to be giving the stock a boost as shares are +4.41% premarket. (PR)

    | May 31, 2013, 8:28 AM
  • May 10, 2013, 8:17 AM

    Dendreon's (DNDN) price target is shaved to $1 by BAML's Rachael McMinn (the axe, according to Notable Calls), who says even this doesn't take into account additional potential dilution. The company's underwater $648M in convertible debt with "no clear path to profitability provides a serious challenge to keep the business in operation beyond 2014." More: Citi downgrades to Sell with $3 PT, and Blair cuts its PT to $2. Shares -4.2% to $3.86 premarket.

    | May 10, 2013, 8:17 AM
  • May 9, 2013, 2:37 PM

    Dendreon (DNDN -14.4%) retests its lows for the day as the Street begins to weigh in on its Q1 miss and dismal Provenge sales numbers. Stifel Nicolaus cuts the shares to Sell, calling Provenge "hopeless," and saying the company is likely to burn through its cash long before it ever reaches breakeven, and faces the possiblity of bankruptcy before the end of FY14. Roth Capital also downgrades the stock to Sell as well.

    | May 9, 2013, 2:37 PM | 1 Comment
  • May 9, 2013, 11:42 AM

    In its call earlier, Dendreon (DNDN -12%) CEO John Johnson attributed its big Q1 miss on Provenge sales to increased competition, with the hit coming hardest in its smaller accounts which are less experienced with injectable therapies like DNDN's. But the veracity in today's selloff may be more closely linked to DNDN's sizeable chunk of convertible notes expiring in 2014 and 2016. Without any real operating income, Seeking Alpha contributor Brian Wilson thinks shareholders are facing some massive dilution on the horizon. (Webcast).

    | May 9, 2013, 11:42 AM
  • May 9, 2013, 10:03 AM

    Dendreon (DNDN -16%) plummets following its earnings miss with Provenge sales of just $67.6M vs. $82M a year ago, and against consensus of around $80M (and low-ball estimates in the low $70M area). "We are seeing an improvement in enrollments," says CEO John Johnson. "As we leverage the power of our DTC campaign, we are confident in our ability to grow Provenge year over year." The earnings call is underway. (PR)

    | May 9, 2013, 10:03 AM
  • May 9, 2013, 8:35 AM
    Dendreon (DNDN): Q1 EPS of -$0.48 misses by $0.01. Revenue of $67.6M misses by $12.55M. (PR)
    | May 9, 2013, 8:35 AM
  • May 9, 2013, 8:30 AM
    Shares of Dendreon (DNDN) are halted with news pending. (Nasdaq T-1 halt)
    | May 9, 2013, 8:30 AM
  • May 9, 2013, 12:05 AM

    Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY

    | May 9, 2013, 12:05 AM
  • May 8, 2013, 5:30 PM

    Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY

    | May 8, 2013, 5:30 PM
  • Mar. 18, 2013, 9:34 AM

    Dendreon (DNDN -1.3%) agrees to pay $40M to settle a class-action investor lawsuit that alleges that the company made "false or misleading statements," particularly about its Provenge cancer drug. Dendreon continues to deny that it made such statements, and says its insurers will pay $38M of the settlement. (PR)

    | Mar. 18, 2013, 9:34 AM | 1 Comment
  • Feb. 25, 2013, 1:40 PM

    Dendreon (DNDN +0.5%) moves up after its Q4 easily beat estimates earlier today. Community accounts, which represent 71% of total sales, were up from 58% Y/Y, with urology +25% overall Q/Q, and oncology up 4%.

    | Feb. 25, 2013, 1:40 PM
  • Feb. 25, 2013, 7:32 AM
    Dendreon (DNDN): Q4 EPS of -$0.30 beats by $0.20. Revenue of $85.5M beats by $2.62M. (PR)
    | Feb. 25, 2013, 7:32 AM
  • Feb. 25, 2013, 12:05 AM
    Notable earnings before Monday’s open: ARIA, BGC, CTB, CWH, DDD, DNDN, FE, HL, HTZ, KWK, LOW, SFL
    | Feb. 25, 2013, 12:05 AM
  • Feb. 24, 2013, 5:30 PM
    Notable earnings before Monday’s open: ARIA, BGC, CTB, CWH, DDD, DNDN, FE, HL, HTZ, KWK, LOW, SFL
    | Feb. 24, 2013, 5:30 PM
Company Description
Dendreon Corp is a biotechnology company. The Company is engaged in the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients.
Sector: Healthcare
Industry: Biotechnology
Country: United States